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cute myocardial infarction
rug-eluting stents
irolimus-eluting stents
ong-term outcome
The efﬁcacy of bare metal stent (BMS) in acute myocardial
nfarction (AMI) has already been conﬁrmed and the CADILLAC trial
howed that major adverse cardiac events (MACE) were signiﬁ-
antly lower in the BMS  group than in the group of old balloon
ngioplasty alone [1]. Regarding the ﬁrst-generation drug-eluting
tent (DES), in the TYPHOON study [2] using sirolimus-eluting
tents (SES) and the HORIZON-AMI study using paclitaxel-eluting
tents (PES) [3], no difference in safety including stent thrombosis
nd all-cause mortality between the groups was found and tar-
et vessel revascularization (TVR) dramatically decreased in the
ES group. Meta-analysis was conducted using 13 randomized tri-
ls and conﬁrmed no signiﬁcant difference in one-year outcome,
eath, and incidence of myocardial infarction (MI) between the
MS and the ﬁrst-generation DES groups or no signiﬁcant differ-
nce in stent thrombosis between the DES and BMS groups. On the
ther hand, DES decreased risks for TVR in chronic phase by 56% in
omparison with BMS  [4].
However, GRACE [5], a clinical data follow-up on AMI  patients
fter DES and BMS  implantation, showed no difference in mortal-
ty 6 months and one year after discharge, but signiﬁcantly higher
ortality in the DES group from 6 months to 2 years and 1 to 2 years,
rawing attention to DES use for ST-elevation myocardial infarction
STEMI). A study using the RESEARCH and T-SEARCH registries [6]
howed no difference in cardiovascular event rate between the DES
nd BMS  groups due to high incidence of very late stent thrombo-
is 3 years after STEMI. Therefore, long-term data on efﬁcacy and
afety of the ﬁrst-generation DES in AMI  patients are required in
apan which has a lower incidence of stent thrombosis compared
ith Europe and the USA.
oncern about stent thrombosis after drug-eluting stent
mplantation in acute myocardial infarctionOne of the major concerns about DES implantation in AMI
atients is acute, subacute, late, and very late stent thrombosis,
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Open access undwhich induce high incidence of cardiac death. Delayed arterial
healing, chronic inﬂammation, late malapposition, and incomplete
reendothelialization are the possible mechanisms for causing stent
thrombosis. The stent size to place in AMI  is decided in the condi-
tions with enormous amounts of thrombosis and vasoconstriction,
consequently, a stent smaller than the vessel diameter is cho-
sen and may  cause malapposition of stents later, resulting in late
stent thrombosis. In the AMI  patients, plaque rupture is involved
in many cases and AMI  patients treated with the ﬁrst-generation
DES had more late stent thrombosis in comparison with patients
with stable lesions [7]. It was also shown that direct coverage of
stent struts in lipidonecrotic core prevented appropriate plaque
recovery and reendothelialization that is usually completed in up
to 6 months in patients treated with BMS  but remained incom-
plete after 40 months in patients treated with DES [8]. Recently,
in-stent neoatherosclerosis has been focused on as a cause of
late-phase stent thrombosis as well as that of in-stent restenosis
after implantation of both DES and BMS  [9]. The involvement of
neoatherosclerosis as a cause of stent thrombosis is more important
in DES than in BMS, because it occurs much earlier after implanta-
tion of stents.
Long-term safety and efﬁcacy of implantation of the ﬁrst
generation drug-eluting stents in patients with and without
acute myocardial infarction in Japan
Since almost no clinical observational study to investigate the
efﬁcacy and safety of DES in AMI  patients in Japan has been con-
ducted to date, a report by Adachi et al. that is published in this issue
[10] is an important article that conﬁrmed long-term (5 years) efﬁ-
cacy and safety of SES in AMI  patients clinically treated in Japan
with a high follow-up rate of 94.5%. In this study, patients were
divided into two groups, the AMI  (n = 133) and non-AMI (n = 1804)
groups and no difference in MACE [all-cause death, MI, any target
lesion revascularization (TLR), and thrombosis], death, MI, or stent
thrombosis was  found during 5-year follow-up. Landmark analy-
sis also used in the j-Cypher registry [11,12] showed signiﬁcantly
higher rates of MACE and death/MI in the AMI group in the early
phase from immediately after stent implantation to 6 months after,
however, signiﬁcantly higher rates of target vessel failure (cardiac
death, recurrent MI,  and TVR) occurred in the non-AMI group in the
late phase. The duration of dual anti-platelet therapy (DAPT) was
similar in both groups and the incidence of hemorrhagic complica-
tions was similar. Also in a sub-analysis of the j-Cypher registry
using the same analysis method [12], adverse events including
er CC BY-NC-ND license.
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eath and MI  occurrence 1–3 years after stent implantation was
imilar between the acute coronary syndrome (ACS) and non-ACS
roups although there was signiﬁcantly lower use of DAPT in the
CS group.
uture direction of percutaneous coronary intervention in
atients with acute myocardial infarction using
rug-eluting stents
One of the most important factors to limit the efﬁcacy of DES
mplantation is the long-term administration of DAPT. DAPT is usu-
lly required for 12 months after implantation of ﬁrst-generation
ES. Medical history is often insufﬁciently considered in many AMI
atients and long-term administration of DAPT makes problems
n many of them. The j-Cypher registry data showed that patients
equiring surgery regardless of major or minor surgery for 3 years
fter DES implantation accounted for 14.7% [13]. The j-Cypher
egistry conﬁrmed that simultaneous discontinuation of aspirin
nd thienopyridine was  a signiﬁcant risk for stent thrombosis at
ny point during long-term follow-up, however, discontinuation
f thienopyridine alone caused no risk 6 months after.
In the second-generation DES that are currently used, i.e.
verolimus-eluting stent (EES) and zotarolimus-eluting stent, the
ecessary administration period of DAPT has been reduced to 3
onths in the CE marking. The EXAMINATION study, a randomized
omparative study of BMS  with EES used for STEMI [14], conﬁrmed
igniﬁcantly lower TLR, the secondary endpoint in the EES group,
lthough no difference in overall endpoints (all-cause mortality, MI,
LR). Surprisingly, the onset of stent thrombosis was  signiﬁcantly
ower in the EES group, therefore, antithrombogenicity of EES poly-
er  may  be involved in stent thrombosis because BMS  in this study
ad the same platform as EES. Furthermore, in the COMFORTABLE-
MI randomized trial using biolimus-eluting stents (BES) with a
iodegradable polymer [15], MACE were signiﬁcantly lower in the
ES group than in that in the BMS  group, mainly due to reduced
arget vessel-related reinfarction and TLR.
onclusions
In Japan, the package insert of coronary stents was revised in
uly 2011 and contraindication for the use in AMI patients was
eleted although even BMS  had been contraindicated for patients
ho developed AMI within one week. DES were also deleted from
ontraindications and described only in precautions, consequently,
he use of DES has been increasing for AMI  patients. In addition, a
eport by Adachi et al. that is published in this issue [10] and the
-Cypher registry [11,12] indicated safety, efﬁcacy, and problems of
he ﬁrst-generation DES used in Japanese AMI patients.
DES implanted for ischemic heart disease switched over from
he ﬁrst generation to second generation resulted in less TVR and
hrombosis in clinical practice in Japan. If the safety and efﬁcacy of
econd-generation DES in AMI  patients are proved also in the real
orld, and a necessary period of DAPT is shortened more, it will be
lmost the day when DES can be implanted in AMI  patients without
ny cautions.
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